BTIG upgraded Edwards Lifesciences (EW) to Buy from Neutral with a $100 price target The firm cites improving stability in the company’s transcatheter aortic valve replacements segment and its positive U.S. doctor feedback on the upcoming catalysts for the upgrade. Edwards’ business performance has been improving steadily in recent months, the analyst tells investors in a research note. BTIG likes the setup for the company’s U.S. TAVR sales and points out that management discussed catalysts like the asymptomatic TAVR launch and a potential update to the TAVR National Coverage Determination that may enable more adoption of the procedure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences upgraded to Outperform from Neutral at Daiwa
- Edwards Lifesciences Reports Strong Growth and Raises Guidance
- Edwards Lifesciences’ MITRIS Valve Study: A Key Development for Investors
- Edwards Lifesciences price target raised to $101 from $89 at Goldman Sachs
- Edwards Lifesciences price target raised to $95 from $87 at Mizuho